01 Shift Toward Tankless and Point-of-Care Nitric Oxide Systems Hospitals are increasingly moving from high-pressure nitric oxide cylinders toward compact systems that generate or store gas at the point of care. These platforms reduce cylinder handling, storage needs, delivery delays, and administrative work while supporting treatment during transfers between neonatal intensive care, operating rooms, and other hospital departments. Built-in monitoring of nitric oxide, oxygen, and nitrogen dioxide also improves workflow and treatment control. Competition is therefore shifting from gas supply alone toward portable devices, integrated safety features, technical support, and flexible hospital contracts. This transition is encouraging established suppliers and newer manufacturers to invest in cylinder-free technologies. In May 2025, Mallinckrodt reported that more than 400 INOmax EVOLVE DS systems had been placed across over 50 U.S. hospitals by the end of March.
01 Growing Need for Rapid Respiratory Support in Critical Care Demand is supported by the need to improve oxygenation in term and near-term newborns with hypoxic respiratory failure linked to pulmonary hypertension. Inhaled nitric oxide selectively relaxes pulmonary blood vessels and can reduce the need for extracorporeal membrane oxygenation when used with ventilatory support. Rising awareness of neonatal respiratory complications, stronger neonatal intensive-care capacity, and broader access to advanced ventilation systems are increasing treatment availability. Respiratory disease also creates research interest beyond neonatal care, including COPD and acute respiratory distress syndrome. The CDC reports that nearly 16 million U.S. adults have COPD, underlining the large respiratory-care burden that encourages further clinical investigation.
01 Limited Approved Uses and High Treatment Costs Market expansion is restricted by the therapy’s narrow approved indication, specialized delivery requirements, and substantial hospital costs. In the United States, approved products primarily treat hypoxic respiratory failure associated with pulmonary hypertension in term and near-term newborns. Adult use remains largely off-label or investigational, limiting routine reimbursement and adoption. Treatment also requires calibrated equipment, continuous gas monitoring, trained respiratory professionals, backup delivery arrangements, and careful dose reduction. These requirements make adoption harder for smaller hospitals and facilities in lower-income regions. Price competition from newer delivery systems is also putting pressure on established brands and changing hospital purchasing decisions.
01 Expansion of Portable Systems and New Clinical Applications Major opportunities are emerging from cylinder-free delivery, geographic expansion, and research into additional respiratory conditions. Systems that generate nitric oxide from room air can reduce dependence on cylinder transport, storage, replacement, and complex supply arrangements. This could improve access in smaller hospitals, emergency settings, and regions with weak medical-gas infrastructure. Manufacturers can also pursue growth through distributor partnerships, hospital purchasing agreements, and devices suitable for transport between care departments. Longer-term opportunities exist in viral pneumonia, COPD, pulmonary hypertension, and acute respiratory distress syndrome, although these applications require strong clinical evidence and regulatory clearance before broad commercialization.
01 Maintaining Safety, Consistent Dosing, and Clinical Evidence Inhaled nitric oxide must be delivered accurately because treatment errors can quickly affect critically ill patients. Nitrogen dioxide may form when nitric oxide mixes with oxygen, potentially causing airway inflammation and lung injury. Higher exposure can also raise methemoglobin levels and reduce the blood’s oxygen-carrying capacity. Abrupt withdrawal may worsen oxygenation and trigger rebound pulmonary hypertension, making controlled weaning essential. Suppliers must therefore provide dependable monitoring, backup delivery, equipment maintenance, clinician training, and uninterrupted service. Another challenge is demonstrating meaningful long-term outcomes beyond temporary oxygenation improvement, especially for adult and off-label applications where evidence remains mixed and regulatory approval is limited.
March 2026 Beyond Air expanded commercialization of its LungFit® PH inhaled nitric oxide delivery system by securing a national group purchasing agreement (GPO) in the United States and expanding its global distribution network to more than 45 countries. The expansion supports broader adoption of cylinder-free nitric oxide generation technology in neonatal intensive care and respiratory care settings.
October 2025 Mallinckrodt Pharmaceuticals continued supporting its INOmax® (nitric oxide) gas therapy platform, which remains one of the established inhaled nitric oxide therapies for neonatal respiratory care. The company maintained focus on supply reliability, clinical support, and healthcare provider access for nitric oxide treatment.
May 2025 VERO Biotech expanded adoption of its GENOSYL® Delivery System, an FDA-approved tankless inhaled nitric oxide delivery platform designed for acute care applications. The company continued strengthening its commercial presence in respiratory care by supporting hospitals with integrated nitric oxide delivery solutions.